Story perspectives

FDA nominee Heidi Overton faces mifepristone safety-review scrutiny

By Drooid · Sep 24, 2026, 11:11 PM UTC · How we work

Center

Senator slams vaccine split

Heidi Overton, President Donald Trump’s FDA nominee, testified before the Senate Health, Education, Labor and Pensions Committee on September 24, 2026.
Committee members noted the FDA has lost more than 3,000 staff in the past year, creating morale challenges.
Senator Bill Cassidy called Overton’s support for splitting measles, mumps and rubella vaccine “almost disqualifying.”
The FDA must file a mifepristone safety-review update with a federal court by October 7.

Left

Abortion stance backlash

Heidi Overton, President Donald Trump’s FDA nominee, testified before the Senate Health, Education, Labor and Pensions Committee on September 24, 2026.
Abortion-rights groups warned Overton’s anti-abortion stance could harm women’s health and damage FDA credibility, calling her unfit.
Overton said the measles, mumps and rubella vaccine and CDC-recommended shots are safe and effective.
The FDA will continue post-market safety reviews, but Overton refused to detail a plan for abortion drug mifepristone.

Blindspot

The Senate HELP Committee hearing highlighted that the FDA has lost more than 3,000 staff in the past year, creating morale challenges.
Within this story's sources, this angle appears mainly in Center-leaning coverage and receives less attention in Left-leaning coverage.

History

Historical Context

Congress enacted the FDA Modernization Act on 21 November 1997, signed by President Bill Clinton, which cut drug review time from 30 months to 15 months. Today, Senate HELP member Bill Cassidy challenges Heidi Overton’s nomination as FDA commissioner while the agency confronts a 3,000-staff loss that endangers the oversight the 1997 law sought to improve.

1 of 4

Senator slams vaccine split

Heidi Overton, President Donald Trump’s FDA nominee, testified before the Senate Health, Education, Labor and Pensions Committee on September 24, 2026.
Committee members noted the FDA has lost more than 3,000 staff in the past year, creating morale challenges.
Senator Bill Cassidy called Overton’s support for splitting measles, mumps and rubella vaccine “almost disqualifying.”
The FDA must file a mifepristone safety-review update with a federal court by October 7.

1 / 4